- Investing Ideas
- U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
6
Companies which are potentially undervalued and in an acceptable financial position.
6 companies
Diaceutics
Market Cap: UK£123.1m
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
DXRX
UK£1.45
7D
-4.6%
1Y
5.5%
AstraZeneca
Market Cap: UK£179.3b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£115.60
7D
-3.6%
1Y
-1.5%
GSK
Market Cap: UK£74.2b
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK
UK£18.52
7D
-3.9%
1Y
28.7%
Oxford Biomedica
Market Cap: UK£596.7m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£4.93
7D
3.0%
1Y
-1.4%
Hikma Pharmaceuticals
Market Cap: UK£3.4b
Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
HIK
UK£16.39
7D
-0.6%
1Y
-9.0%
hVIVO
Market Cap: UK£45.3m
Operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.
HVO
UK£0.066
7D
-3.6%
1Y
-35.6%